MannKind Corporation

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
4.18 USD +2.45% Intraday chart for MannKind Corporation +0.72% +14.84%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
MannKind CFO Binder to Retire in April, Names New CFO MT
MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024 CI
MannKind Corporation Appoints Steven B. Binder as Executive Vice President, Special Projects CI
MannKind Corporation Announces INHALE-3 Study?s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections and Insulin Pumps CI
Transcript : MannKind Corporation, Q4 2023 Earnings Call, Feb 27, 2024
Earnings Flash (MNKD) MANNKIND Reports Q4 Revenue $58.5M, vs. Street Est of $53.1M MT
MannKind Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza® CI
Transcript : MannKind Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 11:15 AM
Transcript : MannKind Corporation - Special Call
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday MT
MannKind Sells 1% Royalty on Tyvaso DPI Net Sales for Up to $200 Million MT
MannKind Restructures Supply Agreement with Amphastar Pharmaceuticals MT
Mannkind Insider Sold Shares Worth $801,928, According to a Recent SEC Filing MT
Oppenheimer Adjusts MannKind Price Target to $5.50 From $6.50, Maintains Outperform Rating MT
Transcript : MannKind Corporation, Q3 2023 Earnings Call, Nov 07, 2023
MannKind Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (MNKD) MANNKIND Reports Q3 Revenue $51.3M, vs. Street Est of $50.7M MT
MannKind Corporation Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living with Type 1 Diabetes CI
MannKind Receives US Patent for Clofazimine Inhalation Suspension to Treat Lung Disease MT
Wedbush Initiates MannKind at Outperform With $10 PT; Says Orphan Lung Pipeline Presents Potential for Real Future Value-Creation, Optionality MT
Transcript : MannKind Corporation Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 08:10 AM
HC Wainwright Adjusts Price Target on MannKind to $7.50 From $7, Keeps Buy Rating MT
Sector Update: Health Care Stocks Mixed Premarket Tuesday MT
MannKind Reports Q2 Breakeven, Revenue Rises MT
Chart MannKind Corporation
More charts
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.18 USD
Average target price
7.083 USD
Spread / Average Target
+69.46%
Consensus
  1. Stock Market
  2. Equities
  3. MNKD Stock
  4. News MannKind Corporation
  5. MannKind to Discuss Results of Phase 1 Study of Inhaled Clofazimine with FDA